Literature DB >> 19404311

Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.

Cyrus DeSouza1, Vivian Fonseca.   

Abstract

The potential cardiovascular risks that are associated with drugs for type 2 diabetes have recently raised considerable clinical and regulatory concerns. As some risk factors for cardiovascular disease and type 2 diabetes are related, identifying agents that target shared underlying pathways and processes is an attractive therapeutic strategy. In this article, we review the background to and the implications of recent regulatory guidance on the development of new drugs for diabetes, and discuss the potential cardiovascular effects of selected classes of diabetes drugs that are currently being investigated.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19404311     DOI： 10.1038/nrd2872

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  70 in total

Review 1.  Intensive insulin treatment in type 2 diabetes.

Authors:  M Arthur Charles
Journal:  Diabetes Technol Ther       Date:  2005-10       Impact factor: 6.118

2.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

Review 3.  Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications.

Authors:  M P Viveros; F Rodriguez de Fonseca; F J Bermudez-Silva; J M McPartland
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-09       Impact factor: 2.895

4.  Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  Xiangdong Su; Nigel Vicker; Melanie Trusselle; Heather Halem; Michael D Culler; Barry V L Potter
Journal:  Mol Cell Endocrinol       Date:  2008-08-15       Impact factor: 4.102

Review 5.  Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.

Authors:  Enrique Z Fisman; Michael Motro; Alexander Tenenbaum
Journal:  Adv Cardiol       Date:  2008

6.  SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes.

Authors:  Takeshi Yoshizaki; Jill C Milne; Takeshi Imamura; Simon Schenk; Noriyuki Sonoda; Jennie L Babendure; Juu-Chin Lu; Jesse J Smith; Michael R Jirousek; Jerrold M Olefsky
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

7.  Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages.

Authors:  Koichi Sugamura; Seigo Sugiyama; Toshimitsu Nozaki; Yasushi Matsuzawa; Yasuhiro Izumiya; Keishi Miyata; Masafumi Nakayama; Koichi Kaikita; Toru Obata; Motohiro Takeya; Hisao Ogawa
Journal:  Circulation       Date:  2008-12-22       Impact factor: 29.690

Review 8.  Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations.

Authors:  Pál Pacher; Partha Mukhopadhyay; Rajesh Mohanraj; Grzegorz Godlewski; Sándor Bátkai; George Kunos
Journal:  Hypertension       Date:  2008-09-08       Impact factor: 10.190

Review 9.  Nuclear factor-kappa B: from clone to clinic.

Authors:  Kwang Seok Ahn; Gautam Sethi; Bharat B Aggarwal
Journal:  Curr Mol Med       Date:  2007-11       Impact factor: 2.222

10.  Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats.

Authors:  James W E Rush; Joe Quadrilatero; Andrew S Levy; Rebecca J Ford
Journal:  Exp Biol Med (Maywood)       Date:  2007-06
View more
  6 in total

Review 1.  Network-based approaches in drug discovery and early development.

Authors:  J M Harrold; M Ramanathan; D E Mager
Journal:  Clin Pharmacol Ther       Date:  2013-09-11       Impact factor: 6.875

2.  Rosiglitazone, PPARγ, and type 2 diabetes.

Authors:  Barbara B Kahn; Timothy E McGraw
Journal:  N Engl J Med       Date:  2010-12-30       Impact factor: 91.245

3.  Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials.

Authors:  Patrick Murray; Gary W Chune; Vasudevan A Raghavan
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

4.  Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome.

Authors:  Haifeng Ye; Ghislaine Charpin-El Hamri; Katharina Zwicky; Matthias Christen; Marc Folcher; Martin Fussenegger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

5.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.

Authors:  Tim Heise; Leo Seman; Sreeraj Macha; Peter Jones; Alexandra Marquart; Sabine Pinnetti; Hans J Woerle; Klaus Dugi
Journal:  Diabetes Ther       Date:  2013-07-10       Impact factor: 2.945

6.  The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

Authors:  Arne Ring; Tobias Brand; Sreeraj Macha; Kerstin Breithaupt-Groegler; Gudrun Simons; Beate Walter; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-04-24       Impact factor: 9.951
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.